MRAs—spironolactone, eplerenone, and finerenone—do far more than nudge blood pressure. They improve outcomes in heart failure, offer targeted benefits in CKD with T2D, and play a unique role in cirrhosis-related ascites. In this focused review, Dr. Busti walks through the why behind the what: aldosterone receptor blockade, tissue selectivity (kidney vs heart), and how those differences drive real-world choices, dosing, and safety.

We compare agents head-to-head, unpack RAAS physiology, and translate it into exam-ready pearls and bedside judgment—covering hyperkalemia risk, gynecomastia, CYP3A4 interactions, ACEi/ARB combinations, and how to counsel on potassium-containing salt substitutes.

Episode highlights

• Choosing the right MRA for HF, resistant HTN, CKD/T2D, primary hyperaldosteronism, and ascites
• Why selectivity and structure (steroidal vs non-steroidal) matter for efficacy and side effects
• Practical monitoring: potassium, renal function, blood pressure, and patient education

Access bonus materials and downloads from the episode at https://www.thisiswhy.health/topics/pharmacology-review-loop-diuretics

Disclaimer: This content is for educational purposes only and is not intended to provide medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have heard in this content.